ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

  • Abstract Number: 1398 • 2019 ACR/ARP Annual Meeting

    Sarilumab and Tocilizumab Receptor Occupancy (RO), and Effects on C-Reactive Protein (CRP) Levels, in Patients with Rheumatoid Arthritis (RA)

    Christine Xu1, Patrick Nolain 2, Qiang Lu 3, Anne Paccaly 4, Melitza Iglesias-Rodriguez 5, Gregory St John 6, Chad Nivens 4, Rafael Maldonado 7, Tomonori Ishii 8, Ernest Choy 9 and Vanaja Kanamaluru 3, 1Sanofi, Bridgewater, NJ, 2Sanofi-Aventis, Montpellier, France, 3Sanofi, Bridgewater, 4Regeneron Pharmaceuticals, Inc., Tarrytown, 5Sanofi Genzyme, Cambridge, MA, 6Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 7Pompeu Fabra University, Barcelona, Spain, 8Tohoku University Hospital, Sendai, Japan, 9Cardiff University School of Medicine, Cardiff, United Kingdom

    Background/Purpose: The in vitro binding affinity of sarilumab (KD 61.9 pM) for the human interleukin-6 receptor (IL-6R) is 15–22-fold higher than that of tocilizumab. This…
  • Abstract Number: L18 • 2018 ACR/ARHP Annual Meeting

    A Randomized Controlled 24-Week Trial Evaluating the Safety and Efficacy of Blinded Tapering Versus Continuation of Long-Term Prednisone (5 mg/day) in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab

    Gerd R. Burmester1, Frank Buttgereit1, Corrado Bernasconi2, Jose Maria Alvaro-Gracia3, Nidia Castro2, Maxime Dougados4, Cem Gabay5, Jacob van Laar6, J. Michael Nebesky2, Attila Pethö-Schramm2, Carlo Salvarani7, Marc Y. Donath8 and Markus R. John2, 1Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, 2F. Hoffmann-La Roche, Basel, Switzerland, 3Hospital Universitario de La Princesa IIS-IP, Madrid, Spain, 4Université Paris-Descartes, Paris, France, 5University Hospitals of Geneva, Geneva, Switzerland, 6University Medical Centre Utrecht, Utrecht, Netherlands, 7Università de Modena e Reggio Emilia, Modena, Italy, 8University Hospital Basel, Basel, Switzerland

    Background/Purpose: Guidelines recommend low-dose, short-duration glucocorticoid (GC) treatment for RA,1,2  but long-term use, especially at prednisone-equivalent doses >5 mg/d, should be avoided.2 Many patients (pts)…
  • Abstract Number: 570 • 2018 ACR/ARHP Annual Meeting

    Evaluation of CXCL13, sICAM1, MMP-3 and S100A8/A9 As Serum Biomarkers in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab

    D. James Haddon, Thierry Sornasse, Michael J. Townsend, Jinglan Pei and Margaret Michalska, Genentech, Inc., South San Francisco, CA

    Background/Purpose: Serum levels of C-X-C motif chemokine ligand 13 (CXCL13) and soluble intercellular adhesion molecule-1 (sICAM-1) have been associated with outcomes in patients with rheumatoid…
  • Abstract Number: 572 • 2018 ACR/ARHP Annual Meeting

    Combining Tocilizumab with Methotrexate Improves Sustainability. Real World Evidence Report from Quebec Database Rhumadata®

    Denis Choquette1, Louis Bessette2, Jacques Brown2, Boulos Haraoui1, Frédéric Massicotte1, Jean-Pierre Pelletier1, Jean-Pierre Raynauld1, Marie-Anaïs Rémillard1, Diane Sauvageau1, Angèle Turcotte2, Édith Villeneuve1 and Louis Coupal1, 1Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, 2Rheumatology, Centre de l'Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada

    Background/Purpose: Biologic therapy targeting TNF have consistently demonstrated better efficacy and effectiveness when combined with a conventional synthetic DMARD (csDMARD), most frequently methotrexate. Although pre-clinical…
  • Abstract Number: 573 • 2018 ACR/ARHP Annual Meeting

    Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis

    Pascal Hilliquin1, Thomas Barnetche2, Guy Baudens3, Ralph Niarra4, Isabelle Idier5 and Alain Saraux6, 1Rheumatology, Hôpital Sud Francilien, Corbeil-Essonne, France, 2Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, 3Rheumatology, CHR Valenciennes, Valenciennes, France, 4Biostatistics, Keyrus of behalf of Roche SAS, Boulogne-Billancourt, France, 5Medical department, Chugai Pharma France, Paris La Defense, France, 6Rheumatology, CHU Brest, Brest, France

    Background/Purpose: In France, tocilizumab (TCZ) subcutaneous (sc) 1st prescription and yearly renewal are restricted to hospital. Monitoring may be done by both office-based or hospital…
  • Abstract Number: 594 • 2018 ACR/ARHP Annual Meeting

    Identification of Tocilizumab Treated RA Patients, Whom Are Not Likely to Show Long-Term Clinical Benefit; Reanalysis of the Biomarker Sub-Study of LITHE

    Anne C. Bay-Jensen1, Christian S. Thudium1, Claus Christiansen2 and Morten A. Karsdal1, 1Nordic Bioscience, Herlev, Denmark, 2Nordic Bioscience, Clinical Development, Herlev, Denmark

    Background/Purpose: Tocilizumab, anti-interleukin 6 receptor (IL-6R) therapy, is an effective treatment of rheumatoid arthritis (RA). However, a significant amount of patients do not respond adequately…
  • Abstract Number: 615 • 2018 ACR/ARHP Annual Meeting

    The Comparative Observational Study about Efficacy, Safety and Adherence between Tocilizumab and Infliximab in Patients with Rheumatoid Arthritis

    Mayumi Matsuda1, Yu Funakubo Asanuma2, Yoshinobu Nakao3, Hiroaki Yazawa2, Takuma Tsuzuki Wada4, Noritsune Kouzu5 and Toshihide Mimura2, 1Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, 2Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 3Department of Rheumatology, Saga University Hospital, Saga, Japan, 4Department of Rheumatology and Applied Immunology, Faculty of Medicine,, Saitama Medical University, Saitama, Japan, 5Saitama Medical University, Moroyama, Japan

    Background/Purpose: Since 2003 in Japan, biologic agents have become widely used for RA patients in whom csDMARDs were ineffective. Tocilizumab (TCZ) was approved for marketing…
  • Abstract Number: 958 • 2018 ACR/ARHP Annual Meeting

    Tocilizumab and the Risk for Cardiovascular Disease Events Among Rheumatoid Arthritis Patients: A Direct Comparison in Real World Setting

    Fenglong Xie1, Huifeng Yun1, Emily Levitan2, Paul M. Muntner2 and Jeffrey R. Curtis1, 1University of Alabama at Birmingham, Birmingham, AL, 2Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Multiple studies have observed unfavorable changes in lipid profile associated with tocilizumab (TCZ, anti-IL6 receptor antagonists) and some other rheumatoid arthritis (RA) therapies. The…
  • Abstract Number: 1174 • 2018 ACR/ARHP Annual Meeting

    Comparative Cost per Response for Four Clinical Outcomes of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial in Patients with Rheumatoid Arthritis

    Jennie H. Best and Jinglan Pei, Genentech, Inc., South San Francisco, CA

    Background/Purpose: The cost-effectiveness of different biologic therapies is an important component in guiding treatment decisions for patients with rheumatoid arthritis (RA). The objective of this…
  • Abstract Number: 1514 • 2018 ACR/ARHP Annual Meeting

    Impact of Comorbidity Burden and Obesity on the Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis

    Dimitrios A. Pappas1, Carol J. Etzel2, Margaux Crabtree3, Jennie H. Best4, Steve Zlotnick4 and Joel Kremer5, 1Columbia University, New York, NY, 2Corrona LLC, Waltham, MA, 3Corrona, LLC, Waltham, MA, 4Genentech, Inc., South San Francisco, CA, 5Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: Few real-world studies have evaluated the impact of comorbidity burden or obesity on the effectiveness of tocilizumab (TCZ) for the improvement of rheumatoid arthritis…
  • Abstract Number: 1543 • 2018 ACR/ARHP Annual Meeting

    The Efficacy, Safety and Adherence of Biologicbiological Disease-Modifying Anti Rheumatic Drugs, Infliximab, Tocilizumab and Abatacept, in Elderly Patients with Rheumatoid Arthritis

    Takuma Tsuzuki Wada1, Yu Funakubo Asanuma2, Mayumi Matsuda3, Hiroaki Yazawa2, Yoshinobu Nakao4, Noritsune Kozu5 and Toshihide Mimura2, 1Department of Rheumatology and Applied Immunology, Faculty of Medicine,, Saitama Medical University, Saitama, Japan, 2Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 3Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, 4Department of Rheumatology, Saga University Hospital, Saga, Japan, 5Kozu Orthopedic Clinic, Yachiyo, Japan

    Background/Purpose: Elderly patients with rheumatoid arthritis (RA) have declined physical performances and increased various complications. We are concerned about decrease of efficacy and increase of…
  • Abstract Number: 1399 • 2017 ACR/ARHP Annual Meeting

    Tissues Are Differently Modulated By Tocilizumab and Methotrexate; Assessment of Connective Tissue Metabolites in the Ambition Study

    Anne C. Bay-Jensen1, Anne Sofie Siebuhr1, Christian S. Thudium2 and Morten Asser Karsdal1, 1Rheumatology, Nordic Bioscience, Herlev, Denmark, 2Biomarkers and Research, Nordic Bioscience, Herlev, Denmark

    Background/Purpose: The response to any treatment in rheumatoid arthritis (RA) is assessed by symptomatic changes, such as swollen joint count and DAS28. However, such assessments…
  • Abstract Number: 1423 • 2017 ACR/ARHP Annual Meeting

    Patterns of Prednisone Use in US Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine Clinical Practice

    Dimitrios A. Pappas1, Carol J. Etzel2, Jennie Best3, Steve Zlotnick3, Taylor Blachley2, Gioia Persuitte2 and Joel Kremer4, 1Columbia University, New York, NY, 2Corrona, LLC, Southborough, MA, 3Genentech, Inc., South San Francisco, CA, 4Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: There are limited data regarding the impact of tocilizumab (TCZ) treatment on prednisone use in patients with rheumatoid arthritis (RA). The objective of this…
  • Abstract Number: 1426 • 2017 ACR/ARHP Annual Meeting

    Higher Levels of Interleukin-6 As Well As Soluble Interleukin-6 Receptor Leads to Worse Clinical and Radiographic Prognosis in Rheumatoid Arthritis Patients Treated with Tocilizumab

    Naoshi Nishina, Yuko Kaneko, Keiko Yoshimoto and Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: We have already reported that baseline levels of soluble interluekin-6 receptor (sIL-6R), target of tocilizumab, predicted response to tocilizumab treatment in rheumatoid arthritis (RA)…
  • Abstract Number: 1439 • 2017 ACR/ARHP Annual Meeting

    Factors Influencing the Prescription of Tocilizumab Alone or in Combination with Dmards in Rheumatoid Arthritis Patients in a Real Life Setting. Pooled Analysis of 2 Observational Studies

    Alain Saraux1, René-Marc Flipo2, Bernard Combe3, Jacques Tebib4, Christelle Baffie5, Isabelle Idier6 and Alain Cantagrel7, 1Rheumatology Department, Rheumatology Department, CHU de la Cavale Blanche, Brest, France, Brest Cedex, France, 2Rheumatology, Department of Rheumatology, CHU Teaching Hospital Lille, France., Lille, France, 3Rheumatology, Lapeyronie Hospital, Montpellier I university, Montpellier, France, 4Rheumatology, University Hospital, Hospices civils de Lyon, Lyon, France, 5Statistics, Altizem on behalf of Roche, Boulogne Billancourt, France, 6Medical department, Chugai Pharma France, Paris La Defense, France, 7Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, Toulouse, France

    Background/Purpose: Tocilizumab (TCZ) as monotherapy (Mono) is nowadays a standard treatment in rheumatoid arthritis (RA) for patients in whom methotrexate (MTX) gives an inadequate response1.…
  • 1
  • 2
  • 3
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology